High level of plasma remnant-like particle cholesterol may predispose to development of hypertension in normotensive subjects

American Journal of Hypertension

Volumn 26, Issue 6, 2013, Pages 793-798

  Kasahara, Akiko ^a   Adachi, Hisashi ^a   Hirai, Yuji ^a   Enomoto, Mika ^a   Fukami, Ako ^a   Yoshikawa, Kuniko ^a   Esaki, Eishi ^a   Yokoi, Kanako ^a   Ogata, Kinuka ^a   Tsukagawa, Eri ^a   Obuchi, Aya ^a   Yoshimura, Ayako ^a   Nakamura, Sachiko ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

blood pressure; epidemiology; hypertension; lipoprotein; prospective study.

Indexed keywords

CHOLESTEROL; REMNANT LIKE LIPOPROTEIN PARTICLE CHOLESTEROL; UNCLASSIFIED DRUG;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

BLOOD PRESSURE; EPIDEMIOLOGY; HYPERTENSION; LIPOPROTEIN; PROSPECTIVE STUDY.;

ADULT; BLOOD PRESSURE; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; JAPAN; LIPOPROTEINS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; RETROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 84877743787     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt011     Document Type: Article

References (38)

1. Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res 1992; 33:369-380.
2. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993; 88:2762-2770.
3. Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 2001; 42:17-21.
4. Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, Tsunoda R, Sakamoto T, Nakano T, Nakajima K, Ogawa H, Sugiyama S, Yoshimura M, Yasue H. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999; 99:2858-2860.
5. Funada J, Sekiya M, Hamada M, Hiwada K. Postprandial elevation of remnant lipoprotein leads to endothelial dysfunction. Circ J 2002; 66:127-132.
6. Maggi FM, Raselli S, Grigore L, Redaelli L, Fantappié S, Catapano AL. Lipoprotein remnants and endothelial dysfunction in the postprandial phase. J Clin Endocrinol Metab 2004; 89:2946-2950.
7. Nakamura T, Takano H, Umetani K, Kawabata K, Obata J, Kitta Y, Kodama Y, Mende A, Ichigi Y, Fujioka D, Saito Y, Kugiyama K. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 2005; 181:321-327.
8. Zheng XY, Liu L. Remnant-like lipoprotein particles impair endothelial function: Direct and indirect effects on nitric oxide synthase. J Lipid Res 2007; 48:1673-1680.
9. Dalla-Riva J, Garonna E, Elliott J, Botham KM, Wheeler-Jones CP. Endothelial cells as target for chylomicron remnants. Atherosclerosis (Supple) 2010; 11:31-37.
10. Ohnishi H, Saitoh S, Takagi S, Ohata J, Isobe T, Kikuchi Y, Takeuchi H, Shimamoto K. Relationship between insulin-resistance and remnantlike particle cholesterol. Atherosclerosis 2002; 164:167-170.
11. Chan DC, Watts GF, Barrett HR, O'Neill FH, Redgrave TG, Thompson GR. Relationships between cholesterol homoeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. Clin Sci 2003; 104:383-388.
12. Shimbo D, Muntner P, Mann D, Viera AJ, Homma S, Polak JF, Barr RG, Herrington D, Shea S. Endothelial dysfunction and the risk of hypertension. The multi-ethnic study of atherosclerosis. Hypertension 2010; 55:1210-1216.
13. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Metabolic precursors of hypertension. Arch Intern Med 1996; 156:1994-2000.
14. Tsuruta M, Hashimoto R, Adachi H, Imaizumi T, Nomura G. Hyperinsulinaemia as a predictor of hypertension: An 11-year followup study in Japan. J Hypertens 1996; 14:483-488.
15. Satoh A, Adachi, H, Tsuruta M, Hirai Y, Hiratsuka A., Enomoto M, Furuki K, Hino A, Takeuchi T, Imaizumi T. High plasma level of remnant-like particle cholesterol in the metabolic syndrome. Diabetes Care 2005; 28:2514-2518.
16. Winkler K, Wetzka B, Hoffmann MM, Friedrich I, Kinner M, Baumstark MW, Zahradnik HP, Wieland H, März W. Triglyceride-rich lipoproteins are associated with hypertension in preeclampsia. J Clin Endocrinol Metab 2003; 88:1162-1166.
17. Koga Y, Hashimoto R, Adachi H, Tsuruta M, Tashiro H, Toshima H. Recent Trends in Cardiovascular Disease and Risk Factors in the Seven Countries Study. Lessons for Science from the Seven Countries Study. A 35-Year Collaborative Experience in Cardiovascular Disease Epidemiology. Springer-Verlag: Tokyo, Japan, 1994, pp 63-74.
18. Hino A, Adachi H, Toyomasu K, Yoshida N, Enomoto M, Hiratsuka A, Hirai Y, Satoh A, Imaizumi T. Very long chain N-3 fatty acids intake and carotid atherosclerosis: An epidemiological study evaluated by ultrasonography. Atherosclerosis 2004; 176:145-149.
19. Nakajima K, Saito T, Tamura, A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E. Cholesterol in remnantlike lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 1993; 223:53-71.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
21. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; on behalf of the collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53:982-992.
22. Lip GYH, Blann A. von Willebrand factor: A marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34:255-265.
23. Mannucci PM. von Willebrand factor: A marker of endothelial damage? Arterioscler Thromb Vasc Biol 1998; 18:1359-1362.
24. Freedman JE, Fabian A, Loscalzo J. Impaired EDRF production by endothelial cells exposed to fibrin monomer and FDP. Am J Physiol 1995; 268:C520-C526.
25. Lip GYH, Blann AD, Beevers DG. Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic hypertension compared with systolic-diastolic hypertension. J Hypertens 1999; 17:1203-1207.
26. Hirooka Y, Imaizumi T, Masaki H, Ando SI, Harada S, Momohara M, Takeshita A. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension 1992; 20:175-180.
27. Imaizumi T, Hirooka Y, Masaki H, Harada S, Momohara M, Tagawa T, Takeshita A. Effects of L-arginine on forearm vessels and responses to acetylcholine. Hypertension 1992; 20:511-517.
28. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium- dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87:1468-1474.
29. Cockcroft JR, Chowienczyk PJ, Benjamin N, Ritter JM. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med 1994; 330:1036-1040.
30. Hall JE, Brands MW, Henegar JR. Mechanisms of hypertension and kidney disease in obesity. Ann NY Acad Sci 1999; 892:91-107.
31. Egan BM. Insulin resistance and the sympathetic nervous system. Curr Hypertens Rep 2003; 5:247-254.
32. Watanabe N, Taniguchi T, Taketoh H, Kitagawa Y, Namura H, Yoneda N, Kurimoto Y, Yamada S, Ishikawa Y. Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes Care 1999; 22:152-156.
33. Twickler TB, Dallinga-Thie GM, Cohn, JS, Chapman MJ. Elevated remnant-like particle cholesterol concentration: A characteristic feature of the atherogenic lipoprotein phenotype. Circulation 2004; 109: 1918-1925.
34. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med 2003; 139:761-776.
35. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension 2007; 49:792-798.
36. Milionis HJ, Liberopoulos EN, Achimastos A, Elisaf MS, Mikhailidis DP. Statins: Another class of antihypertensive agents? J Hum Hypertens 2006; 20:320-335.
37. Liao J, Farmer JA. Statins as adjunctive therapy in the management of hypertension. Curr Atheroscler Rep 2010; 12:349-354.
38. Jonkers IJ, de Man FH, Van Der Laarse A, Frölich M, Gevers Leuven JA, Kamper AM, Blauw GJ, Smelt AH. Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia. J Hypertens 2001; 19:749-755.